Review article: The management of paediatric nonalcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 10, 2014, Pages 1155-1170

  Mitchel, E B ^a   Lavine, J E ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA TOCOPHEROL; BIOLOGICAL FACTOR; DOCOSAHEXAENOIC ACID; FARNESOID X RECEPTOR AGONIST; INSULIN SENSITIZING AGENT; MERCAPTAMINE; METFORMIN; OBETICHOLIC ACID; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TOLL LIKE RECEPTOR MODIFIER; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

BARIATRIC SURGERY; DIET; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EXERCISE; HISTOLOGY; HUMAN; LIFESTYLE MODIFICATION; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PEDIATRIC NONALCOHOLIC FATTY LIVER; PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE; PEDIATRICS; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; CHILD; LIFESTYLE; MOTOR ACTIVITY; NON-ALCOHOLIC FATTY LIVER DISEASE;

CHILD; DIET; HUMANS; LIFE STYLE; MOTOR ACTIVITY; NON-ALCOHOLIC FATTY LIVER DISEASE; VITAMIN E; WEIGHT LOSS;

EID: 84908362139     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12972     Document Type: Review

References (180)

1. Schwimmer JB, Deutsch R, Kahen T, et al,. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-93.
2. Ogden CL, Carroll MD, Curtin LR, et al,. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303: 242-9.
3. Andrews DB, Lavine JE,. Medical therapy for nonalcoholic fatty liver disease in children and adolescents. Expert Rev Gastroenterol Hepatol 2012; 6: 1-3.
4. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE,. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009; 50: 1282-92.
5. Schwimmer JB, Behling C, Newbury R, et al,. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-9.
6. Carter-Kent C, Yerian LM, Brunt EM, et al,. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009; 50: 1113-20.
7. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE,. Review article: epidemiology, pathogenesis and potential treatments of pediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 13-24.
8. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
9. Vajro P, Selvaggia L, Socha P, et al,. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN hepatology committee. J Pediatr Gastroenterol Nutr 2012; 54: 700-13.
10. Giorgio V, Prono F, Graziano F, et al,. Pediatric non-alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013; 13: 40.
11. Vajro P, Lenta S, Pignata C, et al,. Therapeutic options in pediatric nonalcoholic fatty liver disease: current status and future directions. Ital J Pediatr 2012; 38: 55.
12. Ovchinsky N, Lavine JE,. A critical appraisal of advances in pediatric nonalcoholic fatty liver disease. Semin Liver Dis 2012; 32: 317-24.
13. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 142: 1592-609.
14. Perito ER, Rodriguez LA, Lustig RH,. Dietary treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2013; 29: 170-6.
15. Oddy WH, Herbison CE, Jacoby P, et al,. The western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescents. Am J Gastroenterol 2013; 108: 778-85.
16. Hattar LN, Wilson TA, Tabotabo LA, et al,. Physical activity and nutrition attitudes in obese Hispanic children with non-alcoholic steatohepatitis. World J Gastroenterol 2011; 17: 4396-403.
17. Shah K, Stufflebam A, Hilton TN, et al,. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity 2009; 17: 2162-8.
18. Reinehr T, Schmidt C, Toschke AM, et al,. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2 year follow up study. Arch Dis Child 2009; 94: 437-42.
19. Tazawa Y, Noguchi H, Nishinomiya F, et al,. Effect of weight changes on serum transaminase activities in obese children. Acta Paediatr Jpn 1997; 39: 210-4.
20. Fontanella A, Perna C, et al,. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-41.
21. Wang CL, Liang L, Fu JF, et al,. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008; 14: 1598-602.
22. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A,. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-41.
23. Agostoni C, Braegger C, Decsi T, et al,. Role of dietary factors and food habits in the development of childhood obesity: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2011; 52: 662-9.
24. Nobili V, Marcellini M, Devito R, et al,. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44: 458-65.
25. Gronbaek H, Lange A, Birkabaek NH, et al,. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2012; 54: 223-8.
26. Promrat K, Kleiner DE, Niemeier HM, et al,. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
27. Harrison SA, Brunt EM, Fecht WJ, et al,. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH) a randomized prospective trial. Hepatology 2009; 49: 80-6.
28. Nobili V, Manco M, Devito R, et al,. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. Hepatology 2008; 48: 119-28.
29. Yi CX, Al-Massadi O, Donelan E, et al,. Exercise protects against high-fat diet-induced hypothalamic inflammation. Physiol Behav 2012; 106: 485-90.
30. Hannukainen JC, Nuutila P, Borra R, et al,. Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins. J Physiol 2007; 578: 347-58.
31. Tamura Y, Tanaka Y, Sato F, et al,. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90: 3191-6.
32. Kistler KD, Brunt EM, Clark JM, et al,. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011; 106: 460-8.
33. Hickman IJ, Jonsson JR, Prins JB, et al,. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin and quality of life. Gut 2004; 53: 413-9.
34. St. George A, Bauman A, Johnston A, et al,. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50: 68-76.
35. Pollock ML, Franklin BA, Balady GJ, et al,. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 2000; 101: 828-33.
36. Ibanez J, Izquierdo M, Arguelles I, et al,. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 2005; 28: 662-7.
37. Tsuzuku S, Kajioka T, Endo H, et al,. Favorable effects of non-instrumental resistance training on fat distribution and metabolic profiles in healthy elderly people. Eur J Appl Physiol 2007; 99: 549-55.
38. Van Der Heijden GJ, Wang ZJ, Chu Z, et al,. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc 2010; 42: 1972-80.
39. Haskell WL, Nelson ME,. 2008 Physical Activity Guidelines for Americans. Washington, DC: U.S. Department of Health and Human Services, 2008.
40. Huang JS, Barlow SE, Quiros-Tejeira RE, et al,. The NASPGHAN obesity task force: consensus statement: childhood obesity for pediatric gastroenterologists. J Pediatr Gastroenterol Nutr 2013; 56: 99-109.
41. Vos MB, Colvin R, Belt P, et al,. Correlation of vitamin E, uric acid and diet composition with histologic features of pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2012; 54: 90-6.
42. Verduci E, Pozzato C, Banderali G, et al,. Changes of liver fat content and transaminases in obese children after 12-mo nutritional intervention. World J Gastroenterol 2013; 5: 505-12.
43. Westerbacka J, Lammi K, Hakkinen AM, et al,. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90: 2804-9.
44. Kirk E, Reeds DN, Finck BN, et al,. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastrotenterology 2009; 136: 1552-60.
45. Van MC, Abbasi F, Lamendola C, et al,. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 2007; 30: 1075-80.
46. Haufe S, Engeli S, Kast P, et al,. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011; 53: 1504-14.
47. Ouyang X, Cirillo P, Sautin Y, et al,. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-9.
48. Mager DR, Iniguez IR, Gilmour S, et al,. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD). J Parenter Enteral Nutr 2013. Epub ahead of print.
49. Cortez-Pinto H, Jesus L, Barros H, et al,. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006; 25: 816-23.
50. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al,. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-7.
51. Musso G, Gambino R, De Michieli F, et al,. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-16.
52. Yasutake K, Nakamuta M, Shima Y, et al,. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009; 44: 471-7.
53. Kainuma M, Fujimoto M, Sekiya N, et al,. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006; 41: 971-80.
54. Brennan L, Walkley J, Wilks R,. Parent- and adolescent-reported barriers to participation in overweight and obesity intervention. Obesity 2012; 20: 1319-24.
55. Barlow SE, Ohlemeyer CL,. Parent reasons for nonreturn to a pediatric weight management program. Clin Pediatr 2006; 45: 355-60.
56. Barker KB, Palekar NA, Bowers SP, et al,. Non-alcoholic steatohepatitis effects of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101: 368-73.
57. Weiner RA,. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010; 28: 274-9.
58. Holterman A, Gurria J, Tanpure S, DiSomma N,. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Semin Pediatr Surg 2014; 23: 49-57.
59. Dixon JB, Bhathal PS, O'Brien PE,. Weight loss and non-alcoholic fatty liver disease: falls in gammaglutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16: 1278-86.
60. Mathurin P, Hollebecque A, Amalsteen L, et al,. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advance disease. Gastroenterology 2009; 137: 532-40.
61. Pardee PE, Lavine JE, Schwimmer JB,. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 2009; 18: 144-51.
62. Schwimmer JB, Deutsch R, Rauch JB, et al,. Obesity, insulin resistance and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500-5.
63. Apovian CM, Baker C, Ludwig DS, et al,. Best practice guidelines in pediatric/adolescent weight loss surgery. Obes Res 2005; 13: 274-82.
64. Nadler EP, Reddy S, Isenalumhe A, et al,. Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status. J Am Coll Surg 2009; 209: 638-44.
65. Sjostrom L, Narbro K, Sjostrom CD, et al,. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-52.
66. Zelber-Sagi S, Kessler A, Brazowsky E, et al,. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44.
67. Brufani C, Fintini D, Nobili V, et al,. Use of metformin in pediatric age. Pediatr Diabetes 2011; 12: 580-8.
68. Nobili V, Manco M, Ciampalini P, et al,. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month. observational pilot study. Clin Ther 2008; 30: 1168-78.
69. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE,. A phase 2 clinical trial of metformin as treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 21: 871-9.
70. Belfort R, Harrison SA, Brown K, et al,. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
71. Shields WW, Thompson KE, Grice GA, et al,. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis: a pilot study. Ther Adv Gastroenterol 2009; 2: 157-63.
72. Haukeland JW, Konopski Z, Eggesb HB, et al,. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-60.
73. Idilman R, Mizrak D, Corapcioglu D, et al,. Clinical trial: insulin sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 200-8.
74. Duseja A, Das A, Dhiman RK, et al,. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007; 6: 222-6.
75. Nar A, Gedik O,. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009; 46: 113-8.
76. Omer Z, Cetinkalp S, Akyildiz M, et al,. Efficacy of insulin sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 18-23.
77. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H,. Meta-analysis: insulin sensitizers for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35: 66.
78. Lavine JE, Schwimmer JB, Van Natta ML, et al,. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA 2011; 305: 1659-68.
79. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al,. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
80. Ratziu V, Giral P, Jacqueminet S, Charlotte F, et al,. Rosiglitazone for nonalcoholic steatohepatitis: one year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
81. Sanyal AJ, Chalasani N, Kowdley KV, et al,. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
82. Narasimhan S, Gokulakrishnan K, Sampathkumar R, et al,. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 2010; 43: 815-21.
83. Alkhouri N, Berk M, Yerian L, et al,. OxNash score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014. Epub ahead of print.
84. Mandato C, Lucariello S, Licenziati MR, et al,. Metabolic, hormonal, oxidative and inflammatory factors in pediatric obesity related liver disease. J Pediatr 2005; 147: 62-6.
85. Valle A, Catalan V, Rodriguez A,. Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects. Liver Int 2012; 32: 951-61.
86. Hoofnagle JH, Van Natta ML, Kleiner DE, et al,. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatothepatitis. Aliment Pharmacol Ther 2013; 38: 134-43.
87. Lavine JE,. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
88. Murer SB, Aeberli I, Braegger CP, et al,. Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents. J Nutr 2014; 144: 193-201.
89. D'Adamo E, Marcovecchio ML, Giannini C, et al,. Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with vitamin E. Free Radic Res 2013; 47: 146-53.
90. Miller ER III, Pastor-Barriuso R, Dalal D, et al,. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
91. Klein EA, Thompson IM Jr, Tangen CM, et al,. Vitamin E and the risk of prostate cancer: the slenium and vitamin E cancer prevention trial (SELECT). JAMA 2011; 306: 1549-56.
92. Dohil R, Fidler M, Gangoiti JA, et al,. Twice daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 2010; 156: 71-5, e1-e3.
93. Lu SC,. Regulation of glutathione synthesis. Mol Aspects Med 2009; 30: 42-59.
94. Dohil R, Schmeltzer S, Cabrera BL, et al,. Enteric-coated cysteamine for the treatment of pediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 1036-44.
95. Dohil R, Meyer L, Schmeltzer S, et al,. The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects. J Pediatr 2012; 161: 639-45.
96. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH study to test treatment of fatty liver disease in children. Available at: http://www.nih.gov/news/health/jan2012/niddk-11.htm (accessed May 2014).
97. Berardis S, Sokal E,. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr 2014; 173: 131-9.
98. Leuschner UF, Lindenthal B, Herrmann G, et al,. High dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double blind, randomized placebo-controlled trial. Hepatology 2010; 52: 472-9.
99. Orlando R, Azzalini L, Orando S, Lirussi F,. Bile Acids for non-alcoholic fatty liver disease and/or steatohepatitis (Review). The Cochrane Collaboration 2009.
100. Vajro P, Franzese A, Valerio G, et al,. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739-43.
101. Nair S, Cope K, Risby TH, et al,. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 1200-4.
102. Solga SF, Diehl AM,. Nonalcoholic fatty liver disease: lumen-liver interactions and the possible role of probiotics. J Hepatol 2003; 38: 681-7.
103. Thuy S, Ladurner R, Volynets V, et al,. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452-5.
104. Miele L, Valenza V, La Torre G, et al,. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-87.
105. Pappo I, Bercovier EM, Berry Y, et al,. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res 1991; 51: 106-12.
106. Drenick EJ, Fisler J, Johnson D,. Hepatic steatosis after intestinal bypass prevention and reversal of metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82: 535-48.
107. Compare D, Coccoli P, Rocco A, et al,. Gut-liver axis: The impact of gut microbiota on nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22: 471-6.
108. Abu-Shanab A, Quigley EM,. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 691-701.
109. Nardone G, Rocco A,. Probiotics: a potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol 2004; 38 (Suppl. 6): S121-2.
110. Ewashuk J, Endersby R, Thiel D, et al,. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007; 46: 841-50.
111. Ma X, Hua J, Li Z,. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49: 821-30.
112. Velayudham A, Dolganiuc A, Ellis M, et al,. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97.
113. Nardone G, Compare D, Liuori E, et al,. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol 2010; 299: G669-76.
114. Li Z, Yang S, Lin H, et al,. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
115. Aller R, De Luis DA, Izaola O, et al,. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 9: 1090-5.
116. Malaguarnera M, Vacante M, Antic T, et al,. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-53.
117. Wong VWS, Wong GLH, Chim AML, et al,. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12: 256-62.
118. Vajro P, Mandato C, Licenziati MR, et al,. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-3.
119. Ma YY, Li L, Yu CH, et al,. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19: 6911-8.
120. Gibson GR, Roberfroid MB,. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-12.
121. Cani PD, Neyrinck AM, Fava F, et al,. Selective increases of bifidobacteria in gut microflora improve high-fat-diet induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-83.
122. Wang C, Harris WS, Chung M, et al,. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary and secondary prevention studies: a systematic review. Am J Clin Nutr 2006; 84: 5-17.
123. Lombardo YB, Hein G, Chicco A,. Metabolic Syndrome: effects of n3 PUFAs on a model of dyslipemia, insulin resistance and adiposity. Lipids 2007; 42: 427-37.
124. Ishii H, Horie Y, Ohshima S, et al,. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific PTEN-deficient mice. J Hepatol 2009; 50: 562-71.
125. Araya J, Rodrigo R, Videla LA, et al,. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004; 106: 635-43.
126. Pettinelli P, del Pozo T, Araya J, et al,. Enhnacement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophs Acta 2009; 1792: 1080-6.
127. Capanni M, Calella F, Biagini MR, et al,. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-51.
128. Zhu FS, Liu S, Chen XM, et al,. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14: 6395-400.
129. Sofi F, Giangrandi I, Cesari F, Corsani I, et al,. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic liver disease patients: a preliminary study. Int J Food Sci Nutr 2010; 61: 792-802.
130. Spadaro L, Magliocco O, Spampinato D, et al,. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40: 194-9.
131. Tanaka N, Sano K, Horiuchi A, et al,. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413-8.
132. Chen R, Guo Q, Zhu WJ, et al,. Therapeutic efficacy of omega-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease. World Chin J Digestol 2008; 16: 2002-6.
133. Di Minno MND, Russolillo A, Lupoli R, et al,. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18: 5839-47.
134. Parker HM, Johnson NA, Burdon CA, et al,. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-51.
135. Nobili V, Bedogni G, Alisi A, et al,. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomized controlled clinical trial. Arch Dis Child 2011; 96: 350-3.
136. Nobili V, Alisi A, Della CC, et al,. Docosahexaenoic acid for the treatment of fatty liver: randomized controlled trial in children. Nutr Metab Cardiovasc Dis 2013; 23: 1066-70.
137. Nobili V, Carpino G, Alisi A, et al,. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS ONE 2014; 9: e88005.
138. Du J, Ma YY, Yu CH, Li YM,. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2014; 20: 569-77.
139. Zein CO, Yerian LM, Gogate P, et al,. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-9.
140. Van Wagner LB, Koppe SW, Brunt EM, et al,. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10: 277-86.
141. Fuchs M,. Non-alcoholic Fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012; 2012: 934396.
142. Sanyal AJ, Mudaliar S, Henry RR, et al,. A new therapy for nonalcoholic fatty liver disease and diabetes INT 747-the first FXR hepatic therapeutic study. Hepatology 2009; 30: 389A.
143. Adorini L, Pruzanski M, Shapiro D,. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discovery Today 2012; 17: 988-97.
144. Miura K, Seki E, Ohnishi H, et al,. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010; 2010: 362847.
145. Brun P, Castagliuolo I, Di Leo V, et al,. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol 2007; 292: 518-25.
146. Rivera CA, Adegboyega P, van Rooijen N, et al,. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-9.
147. Kanzler H, Barrat FJ, Hessel EM, Coffman RL,. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-9.
148. Ratziu V, Bugianesi E, Dixon J, et al,. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther 2007; 26: 821-30.
149. Fukusato T, Fukushima J, Shiga J, et al,. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 122-7.
150. Loomba R, Wesley R, Pucino F, et al,. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol 2008; 6: 1243-8.
151. Gambino R, Cassader M, Pagano G,. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-49.
152. Nobili V, Parkes J, Bottazzo G, et al,. Performance of ELF serum markers in predicting fibrosis stage in peidatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136: 160-7.
153. Alkhouri N, Carter-Kent C, Lopez R, et al,. A combinaton of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test indentifies children with fibrosis. Clin Gastroenterol Hepatol 2011; 9: 150-5.
154. Fitzpatrick E, Mitra RR, Quaglia A, et al,. Serum levels of CK18 M30 and leptin are useful predictors of steatothepatitis and fibrosis in pediatric NAFLD. J Pediatr Gastroenterol Nutr 2010; 51: 500-6.
155. Vos MB, Barve S, Joshi-Barve S, et al,. Cytokeratin 18, a marker of cell death is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008; 47: 481-5.
156. Shen J, Chan HL, Wong GL, et al,. Noninvasive diagnosis of non-alcoholic steatohepatitis by combined serum markers. J Hepatol 2012; 56: 1363-70.
157. Vuppalanchi R, Jain AK, Deppe R, et al,. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2014. Epub ahead of print.
158. Manco M, Marcellini M, Giannone G, et al,. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 127: 954-60.
159. Kugelmas M, Hill DB, Vivian B, et al,. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-9.
160. Chalasani N, Deeg MA, Crab DW,. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497-502.
161. Schwenzer NF, Springer F, Schraml C, Stefan N, et al,. Noninvasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-45.
162. Shannon A, Alkhouri N, Carter-Kent C, et al,. Ultrasonographic quantitative estimation of hepatic steatosis in children with nonalcoholic fatty liver disease (NAFLD): a prostpective study. J Pediatr Gastroenterol Nutr 2011; 53: 190-5.
163. Saadeh S, Younossi ZM, Remer EM, et al,. The utility of radiologic imaiging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
164. Park SH, Kim PN, Kim KW, et al,. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative assessment. Radiology 2006; 239: 105-12.
165. Rockey DC, Bissell DM,. Noninvasive measures of liver fibrosis. Hepatology 2006; 43 (2 Suppl 1): S113-20.
166. Fitzpatrick E, Quaglia A, Vimalesvaran S, et al,. Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in pediatric chronic liver disease. J Pediatr Gastroenterol Nutr 2013; 56: 72-6.
167. Nobili V, Vizzutti F, Arena U, Abraldes JG, et al,. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-8.
168. Nguyen D, Talwalkar JA,. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 2107-10.
169. De Ledinghen V, Le Bail B, Rebouissoux L, et al,. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, asparate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45: 433-50.
170. Lee CK, Perez-Atayde AR, Mitchel PD, et al,. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. J Pediatr 2013; 163: 1058-64.
171. Petta S, Di Marco V, Camma C, et al,. Reliability of liver stiffness measurement in nonalcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-60.
172. Sasso M, Beaugrand M, de Ledinghen V, et al,. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35.
173. Sasso M, Miette V, Sandrin L, et al,. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36: 13-20.
174. Yin M, Talwalkar JA, Glaser KJ, et al,. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-13, e2.
175. Huwart L, Sempoux C, Vicaut E, et al,. Magnetic resonance elastography for the noninvasive stging of liver fibrosis. Gastroenterology 2008; 135: 32-40.
176. Chen J, Talwalker JA, Yin M, et al,. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56.
177. Dongiovanni P, Anstee QM, Valenti L,. Genetic predisposition in NALFD and NASH: impact on severity of liver disease and response to treatment. Curr Pharmacol Des 2013; 19: 5219-38.
178. Rotman Y, Koh C, Zmuda JM, et al,. The association of genetic variability in patain-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
179. Santoro N, Kursawe R, D'Adamo E, et al,. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52: 1281-90.
180. Nobili V, Donati B, Panera N, et al. A Four-Polymorphisms Risk Score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014; 58: 632-6.